• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肢端肥大症伴初诊口服葡萄糖耐量试验阴性:病例报告。

Acromegaly with initial negative oral glucose tolerance test: a case report.

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan, ROC.

Department of Medicine, MacKay Medical College, New Taipei City, Taiwan, ROC.

出版信息

J Med Case Rep. 2023 Aug 6;17(1):333. doi: 10.1186/s13256-023-04064-z.

DOI:10.1186/s13256-023-04064-z
PMID:37543629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10404368/
Abstract

BACKGROUND

Acromegaly can be diagnosed by a growth hormone value ≥ 1 µg/L following an oral glucose tolerance test. However, normal growth hormone suppression following oral glucose tolerance test may not exclude acromegaly.

CASE PRESENTATION

We present a case of a 55-year-old Chinese man with pituitary macroadenoma incidentally noted after a traffic accident. He reported feet enlargement in the past few years. At the beginning, elevated insulin-like growth factor-1 was noted with growth hormone value < 1 µg/L after oral glucose tolerance test. Fracture-related high insulin-like growth factor-1 was suspected. Insulin-like growth factor-1 decreased gradually but was still above the upper limit of normal . However, he suffered from dizziness 1 year later and insulin-like growth factor-1 increased again. Besides, secondary hypocortisolism developed. The size of the pituitary macroadenoma was stationary. Follow-up oral glucose tolerance test showed a growth hormone value > 1 µg/L. Endoscopic endonasal approach to the remove pituitary macroadenoma was performed subsequently. After the resection of the pituitary macroadenoma, pathology showed positive staining of growth hormone and prolactin. Insulin-like growth factor-1 normalized as well.

CONCLUSIONS

Suppressed growth hormone after oral glucose tolerance test cannot exclude acromegaly, and some patients may have only mild or no clinical presentation of acromegaly. Patients with pituitary microadenoma or macroadenoma and elevated insulin-like growth factor-1 should be closely monitored for signs/symptoms of acromegaly and hypopituitarism.

摘要

背景

口服葡萄糖耐量试验后生长激素值≥1μg/L 可诊断肢端肥大症。然而,口服葡萄糖耐量试验后正常的生长激素抑制并不能排除肢端肥大症。

病例介绍

我们报告了一例 55 岁的中国男性,因交通事故意外发现垂体大腺瘤。他自述近几年脚变大。起初,生长激素值<1μg/L 时发现胰岛素样生长因子-1 升高,怀疑与骨折相关的胰岛素样生长因子-1升高。胰岛素样生长因子-1逐渐下降,但仍高于正常值上限。然而,1 年后他出现头晕,胰岛素样生长因子-1再次升高。此外,还出现了继发性皮质醇功能减退。垂体大腺瘤大小保持稳定。后续的口服葡萄糖耐量试验显示生长激素值>1μg/L。随后采用经鼻内镜入路切除垂体大腺瘤。垂体大腺瘤切除后,病理检查显示生长激素和催乳素阳性染色。胰岛素样生长因子-1也恢复正常。

结论

口服葡萄糖耐量试验后的抑制性生长激素不能排除肢端肥大症,有些患者可能仅有轻度或无肢端肥大症的临床表现。对于胰岛素样生长因子-1升高的垂体微腺瘤或大腺瘤患者,应密切监测肢端肥大症和垂体功能减退的迹象/症状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/74b383f553f2/13256_2023_4064_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/e8f878350b19/13256_2023_4064_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/53b80e06a233/13256_2023_4064_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/74b383f553f2/13256_2023_4064_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/e8f878350b19/13256_2023_4064_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/53b80e06a233/13256_2023_4064_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/74b383f553f2/13256_2023_4064_Fig3_HTML.jpg

相似文献

1
Acromegaly with initial negative oral glucose tolerance test: a case report.肢端肥大症伴初诊口服葡萄糖耐量试验阴性:病例报告。
J Med Case Rep. 2023 Aug 6;17(1):333. doi: 10.1186/s13256-023-04064-z.
2
Acromegaly presenting with low insulin-like growth factor-1 levels and diabetes: a case report.以低胰岛素样生长因子-1水平和糖尿病为表现的肢端肥大症:一例报告
J Med Case Rep. 2015 Oct 30;9:241. doi: 10.1186/s13256-015-0736-z.
3
Reliability of the oral glucose tolerance test in the early postoperative assessment of acromegaly remission.口服葡萄糖耐量试验在肢端肥大症缓解术后早期评估中的可靠性。
J Neurosurg. 2002 Dec;97(6):1282-6. doi: 10.3171/jns.2002.97.6.1282.
4
Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.内镜经蝶窦手术治疗肢端肥大症患者中肿瘤特征及术前术后激素水平对激素缓解的影响。
Neurosurg Focus. 2020 Jun;48(6):E10. doi: 10.3171/2020.3.FOCUS2080.
5
Delayed diagnosis of acromegaly in a patient with focal segmental Glomerulosclerosis: a rare case report and literature review.肢端肥大症患者局灶节段性肾小球硬化的延迟诊断:一例罕见病例报告及文献复习。
BMC Nephrol. 2019 Nov 27;20(1):435. doi: 10.1186/s12882-019-1626-1.
6
Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.肢端肥大症患者术前对促甲状腺激素释放激素的生长激素反应及口服葡萄糖耐量试验:50例患者的回顾性评估
Metabolism. 2002 May;51(5):616-21. doi: 10.1053/meta.2002.32017.
7
Macro-GH - A clinical entity causing a diagnostic challenge - A case report.巨 GH- 一种导致诊断挑战的临床实体-病例报告。
Clin Chim Acta. 2023 Jun 1;546:117392. doi: 10.1016/j.cca.2023.117392. Epub 2023 May 13.
8
Acromegaly with congenital generalized lipodystrophy - two rare insulin resistance conditions in one patient: a case report.肢端肥大症合并先天性全身脂肪营养不良——同一患者的两种罕见胰岛素抵抗病症:病例报告
J Med Case Rep. 2020 Feb 21;14(1):34. doi: 10.1186/s13256-020-2352-9.
9
Caloric restriction as a possible pitfall for persistent acromegaly follow-up - case report.热量限制可能是导致肢端肥大症持续随访的一个陷阱 - 病例报告。
BMC Endocr Disord. 2023 Mar 27;23(1):68. doi: 10.1186/s12902-023-01319-0.
10
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.年龄会改变肢端肥大症术后患者口服葡萄糖后平均生长激素水平和生长激素最低点水平的诊断准确性。
Clin Endocrinol (Oxf). 2006 Aug;65(2):250-6. doi: 10.1111/j.1365-2265.2006.02584.x.

引用本文的文献

1
Silent growth hormone pituitary adenomas: a single-center study.沉默型垂体生长激素腺瘤:一项单中心研究
Pituitary. 2025 Sep 11;28(5):99. doi: 10.1007/s11102-025-01574-5.

本文引用的文献

1
Subclinical acromegaly: to treat or not to treat?亚临床肢端肥大症:治疗还是不治疗?
Endocr J. 2022 Nov 28;69(11):1323-1328. doi: 10.1507/endocrj.EJ22-0066. Epub 2022 Jun 22.
2
Diagnosis and Treatment of Acromegaly: An Update.肢端肥大症的诊断与治疗:最新进展。
Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007.
3
Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load.肢端肥大症患者口服葡萄糖负荷后 GH 反常升高的特征及治疗反应性。
Eur J Endocrinol. 2021 Jul 1;185(2):313-321. doi: 10.1530/EJE-21-0324.
4
The Biochemical Diagnosis of Acromegaly.肢端肥大症的生化诊断
J Clin Med. 2021 Mar 9;10(5):1147. doi: 10.3390/jcm10051147.
5
Multidisciplinary management of acromegaly: A consensus.肢端肥大症的多学科管理:共识。
Rev Endocr Metab Disord. 2020 Dec;21(4):667-678. doi: 10.1007/s11154-020-09588-z. Epub 2020 Sep 10.
6
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.肢端肥大症合并症的诊断与治疗共识:更新版。
J Clin Endocrinol Metab. 2020 Apr 1;105(4). doi: 10.1210/clinem/dgz096.
7
Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 µg/L but < 1 µg/L.对胰岛素样生长因子-1升高且生长激素最低点>0.4μg/L但<1μg/L的患者进行长期随访。
Arch Endocrinol Metab. 2017 Sept-Oct;61(5):426-431. doi: 10.1590/2359-3997000000295. Epub 2017 Sep 18.
8
Acromegaly: an endocrine society clinical practice guideline.肢端肥大症:内分泌学会临床实践指南。
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51. doi: 10.1210/jc.2014-2700. Epub 2014 Oct 30.
9
Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.从出生到衰老的胰岛素样生长因子-1(IGF-1)参考区间:使用符合最近国际建议的新型自动化化学发光 IGF-I 免疫分析法进行的多中心研究结果。
J Clin Endocrinol Metab. 2014 May;99(5):1712-21. doi: 10.1210/jc.2013-3059. Epub 2014 Feb 27.
10
Clinically silent somatotroph adenomas are common.临床上无功能的生长激素腺瘤很常见。
Eur J Endocrinol. 2011 Jul;165(1):39-44. doi: 10.1530/EJE-11-0216. Epub 2011 Apr 14.